From: Minocycline black bone disease in arthroplasty: a systematic review
Study | Age | Joint | Indication | Fixation | Components | Subchondral bone | Minocycline dose (cumulative, g) | Follow-up (years) | Outcome—pain | Outcome—function |
---|---|---|---|---|---|---|---|---|---|---|
Ashukem et al. (2016) | Not noted | Primary shoulder | OA | Uncemented stem, cemented glenoid | Press-fit humeral stem, cemented pegged glenoid (DJO Turon) | Greyish-black | Unspecified | 0.5 | Little to no pain | Normal ADLs, return of ROM, stable shoulder |
Chauhan and McDougall (2014) | 82 | Primary knee (bilateral) | OA | Â | Â | Black, normal cancellous bone | Â | Â | Â | Â |
McCleskey and Littleton (2004) | 81 | Primary knee (right) | OA | Cemented | Unspecified | Blue-green-grey | ~73 | 1 | Â | Return of ROM, stable knee |
Reed, Gregg, and Corpe (2012) | 55 | Primary knee (left) | OA | Cemented | Not noted, patella not resurfaced | Black, normal cancellous bone | > 365 | 0.25 | No pain | Normal ADLs, return of ROM, stable knee |
Yang et al. (2012) | 75 | Primary ankle | Reactive arthritis | Â | Fine total ankle | Black | 140 | 4.6 | Occasional arthritic pain | Normal ADLs |
 | 49 | Primary knee | RA |  | Biomet Vanguard | Black | 131 | 2.8 | No pain | Normal ADLs |
 | 77 | Revision knee | OA |  | Zimmer Nexgen LCCK | Black | 176 | 2 | Not noted—multiple cerebral infarctions at 2 years | |
 | 48 | Primary hip | RA |  | Zimmer ZCA cup and CPT stem | Black | 94.3 | 3.8 | No pain | Normal ADLs |
 | 33 | Revision hip | Sarcoidosis |  | Zimmer ZCA cup with JMM KT plate, Zimmer CPT stem | Black | 42.5 | 3.6 | No pain | Normal ADLs |
This study (2021) | 57 | Primary knee (right) | OA | Cemented | Stryker Triathlon PS, patella resurfaced | Black | 584 | 4 | No pain | Normal ADLs, return of ROM, stable knee |
 | 59 | Primary knee (left) | OA | Cemented | Stryker Triathlon CR, patella not resurfaced | Black | 621 | 2 | No pain | Normal ADLs, return of ROM, stable knee |